Publication | Open Access

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Breast OncologyMedicinePharmacologyBreast CancerPi3k InhibitorAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology